NCT01502124 - Safety and Efficacy of Somatropin in Children With Growth Hormone Deficiency | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 8, 2001

Primary Completion Date

March 5, 2003

Study Completion Date

March 5, 2003

Conditions

Growth Hormone DisorderGrowth Hormone Deficiency in Children

Interventions

DRUG

somatropin

Injected subcutaneously 7 times per week after reconstitution with liquid buffer prior to use. Dose level of 0.024-0.050 mg/kg at the discretion of the practicing paediatric endocrinologists

DRUG

somatropin

Injected subcutaneously 7 times per week. Dose level of 0.024-0.050 mg/kg at the discretion of the practicing paediatric endocrinologists

Trial Locations (21)

11030

Novo Nordisk Investigational Site, Manhasset

15212

Novo Nordisk Investigational Site, Pittsburgh

15224

Novo Nordisk Investigational Site, Pittsburgh

17033

Novo Nordisk Investigational Site, Hershey

19899

Novo Nordisk Investigational Site, Wilmington

20010

Novo Nordisk Investigational Site, Washington D.C.

30342

Novo Nordisk Investigational Site, Atlanta

32608

Novo Nordisk Investigational Site, Gainesville

33155

Novo Nordisk Investigational Site, Miami

33607

Novo Nordisk Investigational Site, Tampa

40202

Novo Nordisk Investigational Site, Louisville

60612

Novo Nordisk Investigational Site, Chicago

60614

Novo Nordisk Investigational Site, Chicago

67226

Novo Nordisk Investigational Site, Wichita

90027

Novo Nordisk Investigational Site, Los Angeles

98105

Novo Nordisk Investigational Site, Seattle

90048-1869

Novo Nordisk Investigational Site, Los Angeles

32806-1101

Novo Nordisk Investigational Site, Orlando

40536-0284

Novo Nordisk Investigational Site, Lexington

01655

Novo Nordisk Investigational Site, Worcester

44308-1062

Novo Nordisk Investigational Site, Akron